( Studies in Mice Show Reduction of Enzym...)Amicus Therapeutics Presents Data From Preclinical and Phase 1,Studies of Amigal for Fabry Disease,Health

CRANBURY, N.J., March 19, 2007 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today that the Company will present results from studies of Amigal(TM) (migalastat hydrochloride, AT1001), Amicus' compound in development for the treatment of Fabry disease, at the of Medical Genetics (ACMG) Annual Meeting from March 21-25 in Nashville, TN. This presentation will include the first data from the Company demonstrating the reduction of globotriaosylceramide (GL-3), the lipid substrate that accumulates in Fabry disease, after oral administration of a pharmacological chaperone. These data were not available at the time of abstract submission but will be included in the presentation at the meeting.

Amigal is designed to selectively bind to and stabilize alpha- galactosidase A (alpha-GAL), the enzyme deficient in Fabry disease. This deficiency leads to lysosomal accumulation of GL-3, which is believed to cause the various symptoms of Fabry disease. Amigal facilitates proper trafficking of the enzyme to the lysosomes, the compartments in the cell where it is needed to break down GL-3.

At the ACMG meeting, Amicus scientists will present data from several studies that examined the in vitro and in vivo effects of Amigal in cell lines, mice and healthy volunteers. Among the key findings:

    - In vitro exposure to Amigal increased the level of alpha-GAL in cells

      derived from healthy volunteers and from Fabry patients.


    - Oral administration of Amigal resulted in a dose-dependent increase in

      alpha-GAL levels in various tissues of normal mice and Fabry mice

      genetically modified to produce alpha-GAL with a human missense

      mutation.


    - Oral administration of Amigal to healthy vo
'"/>




Page: 1 2 3 
Related medicine technology :

1. Amicus Therapeutics Presents Positive Results From Phase 1 Clinical
Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Preclinical Data from Studies of
Plicera for Gaucher Disease
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement
of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of
Action for Ranexa
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into
Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to
Sustained Reductions in Blood Glucose Levels for 6 Months
Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for
Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical
Study
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II
Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on
Visceral Fat and Insulin Resistance at American Diabetes
Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of
Efaproxyn in Women With Brain Metastases Originating From Breast
Cancer